Clinical trials: Iatrogenic Disorder
Pneumonia, Ventilator-Associated
Removing Fluid Above Breathing Tubes in the Operating Room
In this study, subjects meeting criteria will be enrolled and randomized to one of two different suctioning schemes, either continuous or intermittent.
- Trial name
- NCT01110109
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Medtronic - MITG
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including…
- Conditions
- Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
- Trial name
- RECOMMEND (NCT02364284)
- Where
- 27 sites in Brazil, France and 4 more
- Volunteers
- 1,322 people
- Sponsor
- Pfizer
Nosocomial Infection, Diarrhea, Infantile
Effect and Tolerability of Lactobacillus Rhamnosus GG LA801 for the Preventive Nutritional Care of Nosocomial Diarrhea in Children
One of the most common infections acquired in hospital, also known as nosocomial infections, is intestinal infections. These infections can lead to the development of nosocomial diarrhea which can have serious consequences in…
- Trial name
- EPISODE (NCT04628819)
- Where
- 2 sites in France
- Volunteers
- 61 people
- Sponsor
- PiLeJe
Ventilator-associated Pneumonia, Hospital-acquired Pneumonia
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.
- Trial name
- CERTAIN-2 (NCT06168734)
- Testing
- Cefepime-taniborbactam, Meropenem
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Pneumonia, Ventilator-Associated
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
Given the challenges of treating complex cases of VAP caused by P. aeruginosa and K. pneumoniae, TechnoPhage developed a bacteriophage cocktail (TP-122) against those pathogens, aiming to provide a hospital-based add-on therapy…
- Trial name
- RECOVER (NCT06370598)
- Testing
- TP-122A
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Technophage, SA
Gram-Positive Bacterial Infections, Cross Infection
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
- Trial name
- NCT00081744
- Testing
- Tigecycline
- Volunteers
- 850 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica
Complicated Skin and Structure Infection, Nosocomial Pneumonia
Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients
This is a retrospective, observational, non-interventional drug study using de-identified data from two administrative claims datasets. The study design and analysis will reflect the perspective of the commercially insured.
- Trial name
- NCT01363271
- Testing
- Linezolid, Vancomycin
- Volunteers
- 7,260 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen…
- Conditions
- Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia
- Trial name
- NCT05733104
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Ventilator-Associated Pneumonia (VAP)
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of…
- Trial name
- NCT01853982
- Testing
- Ceftolozane/Tazobactam, Piperacillin/Tazobactam
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 4 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumonia
Doripenem in the Treatment of Hospital-Acquired Pneumonia
The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).
- Trial name
- NCT00211003
- Testing
- doripenem
- Volunteers
- 240 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pneumonia
Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia
This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and…
- Trial name
- NCT00118781
- Testing
- iseganan hydrochloride
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- IntraBiotics Pharmaceuticals
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Pseudomonas Aeruginosa, Ventilator Associated Pneumonia
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen that rarely causes disease in healthy people, but is a significant problem for critically ill or immunocompromised individuals.
- Trial name
- NCT00691587
- Testing
- KB001
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Humanigen, Inc.
Ventilator Associated Pneumonia, Staphylococcus Aureus
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE-2 (NCT05331885)
- Testing
- Suvratoxumab
- Where
- 27 sites in Belgium, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Leakage After Esophagectomy, Leakage After Gastrectomy
Eso-Sponge Registry
This international, prospective and multicenter registry was designed to collect clinical evidence for the endoscopic vacuum treatment using Eso-SPONGE® for anastomotic leakage after esophageal resection or iatrogenic or…
- Conditions
- Leakage After Esophagectomy, Leakage After Gastrectomy, Perforation of the Esophagus
- Trial name
- NCT02662777
- Testing
- Eso-SPONGE® vacuum treatment
- Where
- 17 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Aesculap AG
Sacroiliitis, Sacroiliac Joint Dysfunction
Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device
The purpose of this clinical study is to evaluate fusion of the SI joint(s) and any reduction in VAS pain scores in a prospective cohort of patients utilizing the SiJoin® Transfixing Sacroiliac Fusion Device in patients that…
- Conditions
- Sacroiliitis, Sacroiliac Joint Dysfunction, Iatrogenic Injury, Osteitis Condensans Ilii
- Trial name
- NCT05712850
- Testing
- SiJoin® Transfixing Sacroiliac Fusion Device
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- VG Innovations, LLC
Nosocomial Infections, Pneumonia, Ventilator-Associated
A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization
The study is a first step in establishing the safety and efficacy of the CytaCoat technology when applied to a medical device such as a nasal prong and the clinical data generated will serve as a basis for continuous studies in…
- Trial name
- NCT02756351
- Testing
- CytaCoat Nasal Prong, Inspiration Healthcare Inspire nCPAP Nasal Prong
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- CytaCoat AB